Ohio is currently home to 3225 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Cincinnati, Columbus, Cleveland and Dayton. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Once Weekly Infant Corticosteroid Trial for DMD
NCT05412394
Recruiting
The hypothesis tested here is that a lower dose of intermittent oral corticosteroids (5mg/kg/week) will be equally effective to the 10mg/kg/week dose.
Gender:
MALE
Ages:
Between 1 month and 30 months
Trial Updated:
02/11/2025
Locations: University of Cincinnati, Cincinnati, Ohio
Conditions: Duchenne Muscular Dystrophy
Register for Updates
STOP Persistent AF PAS
NCT05005949
Recruiting
The STOP Persistent AF Post Approval Study (PAS) is a prospective, global, multicenter, observational trial.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/11/2025
Locations: The Lindner Research Center, Cincinnati, Ohio
Conditions: Persistent Atrial Fibrillation
Register for Updates
Evaluation of Lomecel-Bā„¢ Injection in Patients With Hypoplastic Left Heart Syndrome (HLHS): A Phase IIb Clinical Trial.
NCT04925024
Recruiting
The purpose of this study is to test whether Lomecel-Bā„¢ works in treating patients with hypoplastic left heart syndrome (HLHS) and to gather additional information about the safety of Lomecel-B. Lomecel-B contains human mesenchymal stem cells (MSCs) as the active ingredient. MSCs are special cells in the body that are able to change into other types of cells, such as heart, blood, and muscle cells. MSCs are found in various tissues of the body, such as the bone marrow, which is the spongy tissue... Read More
Gender:
ALL
Ages:
12 months and below
Trial Updated:
02/11/2025
Locations: Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
Conditions: Hypoplastic Left Heart Syndrome
Register for Updates
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
NCT04870944
Recruiting
This phase I/II trial evaluates the best dose, side effects and possible benefit of CBL0137 in treating patients with solid tumors, including central nervous system (CNS) tumors or lymphoma that has come back (relapsed) or does not respond to treatment (refractory). Drugs, such as CBL0137, block signals passed from one molecule to another inside a cell. Blocking these signals can affect many functions of the cell, including cell division and cell death, and may kill cancer cells.
Gender:
ALL
Ages:
Between 12 months and 30 years
Trial Updated:
02/11/2025
Locations: Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
Conditions: Diffuse Midline Glioma, H3 K27M-Mutant, Metastatic Malignant Neoplasm in the Central Nervous System, Recurrent Diffuse Intrinsic Pontine Glioma, Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Osteosarcoma, Recurrent Primary Malignant Central Nervous System Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Osteosarcoma, Refractory Primary Malignant Central Nervous System Neoplasm
Register for Updates
VITAS: Atezolizumab in Combination with Chemotherapy for Pediatric Relapsed/refractory Solid Tumors
NCT04796012
Recruiting
This trial is a multi-center, non-randomized, open-label Phase I/II study evaluating the feasibility and efficacy of vincristine, irinotecan, temozolomide, and atezolizumab in children with relapsed/refractory solid tumors.
Gender:
ALL
Ages:
Between 6 months and 30 years
Trial Updated:
02/11/2025
Locations: Cincinnati Children's Hospital, Cincinnati, Ohio
Conditions: Solid Tumor, Rhabdomyosarcoma
Register for Updates
ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)
NCT04363684
Recruiting
ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD) represents the formalized integration of ARTFL (U54 NS092089; funded through 2019) and LEFFTDS (U01 AG045390; funded through 2019) as a single North American research consortium to study FTLD for 2019 and beyond.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/11/2025
Locations: Case Western Reserve Medical Center, Cleveland, Ohio
Conditions: Frontotemporal Lobar Degeneration (FTLD), Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration (CBD), Behavioral Variant Frontotemporal Dementia (bvFTD), Semantic Variant Primary Progressive Aphasia (svPPA), Nonfluent Variant Primary Progressive Aphasia (nfvPPA), FTD With Amyotrophic Lateral Sclerosis (FTD/ALS), Amyotrophic Lateral Sclerosis, Oligosymptomatic PSP (oPSP), C9orf72, GRN Related Frontotemporal Dementia, MAPT Gene Mutation, TBK1 Gene Mutation, Oligosymptomatic Progressive Supranuclear Palsy
Register for Updates
AB-1002 in Patients With Class III Heart Failure
NCT04179643
Recruiting
This is a Phase 1, prospective, multi-center, open-label, sequential dose escalation study to explore the safety, feasibility, and efficacy of a single intracoronary infusion of AB-1002 in patients with NYHA Class III heart failure. Patients with non-ischemic cardiomyopathy will be enrolled until up to 17 subjects have received infusions of investigational product. All patients will be followed until 12 months post treatment intervention, and then undergo long-term follow-up via semi-structured... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/11/2025
Locations: The Linder Center for Education and Research at The Christ Hospital, Cincinnati, Ohio
Conditions: Congestive Heart Failure, Heart Failure, Heart Disease, Ischemic, Cardiovascular Diseases, Heart Failure, Systolic, Heart Failureļ¼ŒCongestive, Heart Arrhythmia, Heart Failure, Diastolic, Heart; Complications
Register for Updates
Freedom-1 Study for Chronic Knee Pain
NCT03877653
Recruiting
To demonstrate the potential benefits and risk of active sub-threshold stimulation in the treatment of chronic knee pain as compared to subjects that did not have active stimulation. Improvement will be assessed in relation to the clinical outcome measures of pain, with primary endpoint; Pain relief rate as measured by the number of subjects with greater or equal to a 50% decrease in pain on the visual analog scale, comparing baseline to the 1-month follow-up.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/11/2025
Locations: Orthopedic Associates of Southwest Ohio, Dayton, Ohio
Conditions: Osteoarthritic Knee Pain
Register for Updates
VCRC Tissue Repository
NCT02967068
Recruiting
The purpose of this study is to collect existing tissue specimens from subjects enrolled in Vasculitis Clinical Research Consortium (VCRC) studies. Analysis of these tissue specimens and linked clinical data collected through VCRC studies may lead to the identification and development of a series of translational research projects. Results of these studies will provide vasculitis researchers with insight into the causes of these diseases and generate new ideas for diagnostic tests and therapies,... Read More
Gender:
ALL
Ages:
All
Trial Updated:
02/11/2025
Locations: Cleveland Clinic, Cleveland, Ohio
Conditions: Aortitis, Cutaneous Vasculitis, Eosinophilic Granulomatosis With Polyangiitis, Giant Cell Arteritis, Granulomatosis With Polyangiitis (Wegener's), Henoch-Schonlein Purpura, IgA Vasculitis, Microscopic Polyangiitis, Polyarteritis Nodosa, Takayasu Arteritis, Churg-Strauss Syndrome
Register for Updates
Generic Database of Very Low Birth Weight Infants
NCT00063063
Recruiting
The Generic Database (GDB) is a registry of very low birth weight infants born alive in NICHD Neonatal Research Network (NRN) centers. The GDB collects observational baseline data on both mothers and infants, and the therapies used and outcomes of the infants. The information collected is not specific to a disease or treatment (i.e., it is "generic"). Data are analyzed to find associations and trends between baseline information, treatments, and infant outcome, and to develop future NRN trials.
Gender:
ALL
Ages:
14 days and below
Trial Updated:
02/11/2025
Locations: Cincinnati Children's Medical Center, Cincinnati, Ohio
Conditions: Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature
Register for Updates
Follow-up Visit of High Risk Infants
NCT00009633
Recruiting
The NICHD Neonatal Research Network's Follow-Up study is a multi-center cohort in which surviving extremely low birth-weight infants born in participating network centers receive neurodevelopmental, neurosensory and functional assessments at 22-26 months corrected age (Infants born prior to July 1, 2012 were seen at 18-22 months corrected age). Data regarding pregnancy and neonatal outcome are collected prospectively. The goal is to identify potential maternal and neonatal risk factors that may... Read More
Gender:
ALL
Ages:
Between 18 months and 26 months
Trial Updated:
02/11/2025
Locations: Cincinnati Children's Medical Center, Cincinnati, Ohio
Conditions: Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature
Register for Updates
A Study to Evaluate the Safety and Tolerability of Efgartigimod PH20 SC Given by Prefilled Syringe in Kidney Transplant Recipients with Antibody-Mediated Rejection (AMR)
NCT06503731
Recruiting
The purpose of this study is to assess the safety, tolerability, and efficacy of efgartigimod PH20 SC given by a prefilled syringe in participants with Antibody-Mediated Rejection (AMR) after kidney transplantation. After a screening period of up to 6 weeks, eligible participants will be randomized in a 1:1:1 ratio. The study drug will be administered subcutaneously while patients remain on their standard background immunosuppression therapy (tacrolimus, mycophenolate mofetil, steroids) during... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
02/10/2025
Locations: The Ohio State University Wexner Medical Center, Columbus, Ohio
Conditions: Antibody-mediated Rejection
Register for Updates